<DOC>
	<DOCNO>NCT02412592</DOCNO>
	<brief_summary>Chronic hepatitis B ( CHB ) serious liver disease worldwide , lead cause cirrhosis hepatocellular carcinoma ( HCC ) . HBeAg seroconversion consider satisfied endpoint antiviral therapy HBeAg-positive chronic hepatitis B patient . However , HBV reaction , even reverse back HBeAg positive clinical relapse could occur patient achieve HBeAg seronconversion interferon treatment . In study , long-term efficacy interferon therapy HBeAg positive patient achieve HBeAg seronconversion interferon treatment factor associate viral clinical relapse observe .</brief_summary>
	<brief_title>Sustained Viral Response Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon Therapy</brief_title>
	<detailed_description>HBeAg positive chronic hepatitis B patient achieve HBeAg seronconversion interferon treatment enrol observe 156 week . Serum HBV DNA , HBsAg , anti-HBs , HBeAg , anti-HBe measure every 3 month observation period , liver function test perform every 3 month also . The liver ultrasonic examination would take every 3-6 month . The primary endpoint sustain viral response , secondary endpoint HBV DNA reaction clinical relapse define virla relapse abnormal ALT observation period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>patient achieve HBeAg seroconversion interferon treatment . Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HBeAg positive</keyword>
	<keyword>interferon</keyword>
	<keyword>peginterferon</keyword>
	<keyword>HBeAg seroconversion</keyword>
	<keyword>sustain viral response</keyword>
	<keyword>relapse</keyword>
</DOC>